RxSight, Inc. (NASDAQ:RXST) Shares Bought by Swiss National Bank

Swiss National Bank lifted its position in shares of RxSight, Inc. (NASDAQ:RXST) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 66,300 shares of the company’s stock after buying an additional 1,700 shares during the period. Swiss National Bank owned approximately 0.16% of RxSight worth $2,279,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Quest Partners LLC increased its stake in RxSight by 346.1% during the third quarter. Quest Partners LLC now owns 3,069 shares of the company’s stock worth $152,000 after acquiring an additional 2,381 shares during the last quarter. Intech Investment Management LLC acquired a new stake in RxSight during the 3rd quarter worth approximately $598,000. Charles Schwab Investment Management Inc. raised its holdings in RxSight by 28.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 285,329 shares of the company’s stock valued at $14,104,000 after buying an additional 62,507 shares during the period. Larson Financial Group LLC lifted its position in RxSight by 55.8% during the third quarter. Larson Financial Group LLC now owns 1,536 shares of the company’s stock valued at $76,000 after buying an additional 550 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in RxSight during the third quarter worth approximately $605,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RXST. JPMorgan Chase & Co. cut their target price on shares of RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus cut their price objective on RxSight from $33.00 to $28.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Wells Fargo & Company decreased their target price on RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. UBS Group started coverage on RxSight in a report on Friday, December 6th. They set a “buy” rating and a $52.00 target price on the stock. Finally, Bank of America decreased their price target on RxSight from $60.00 to $36.00 and set a “buy” rating for the company in a report on Friday, March 21st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Insider Activity

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jesse Anderson Corley purchased 1,443 shares of RxSight stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the completion of the transaction, the director now owns 1,443 shares in the company, valued at approximately $44,992.74. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 9.36% of the company’s stock.

RxSight Stock Up 9.4 %

RXST stock opened at $26.67 on Friday. The stock’s 50 day moving average is $29.18 and its two-hundred day moving average is $39.35. RxSight, Inc. has a 52-week low of $24.09 and a 52-week high of $66.54. The company has a market capitalization of $1.08 billion, a PE ratio of -32.13 and a beta of 1.22.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The company had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. As a group, sell-side analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.